Exchange: NASDAQ·Updated 04:10 PM EST

DSGN News

News
all
press releases
Design Therapeutics, Inc. (NASDAQ:DSGN) Stock Rated "Moderate Buy" by Sell-Side Analysts
Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a...
MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Stock Rated "Moderate Buy" by Sell-Side Analysts
Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a...
MarketBeat
More News
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.
Zacks
AstraZeneca faces a longer FDA review for camizestrant combo in a certain type of first-line breast cancer after regulators request additional data.
Zacks
AstraZeneca and Daiichi Sankyo get FDA approval for Datroway's expanded use in triple-negative breast cancer treatment.
Zacks
Design Therapeutics reported Phase 1/2 data for DT-216P2, showing biomarker and clinical improvements in Friedreich ataxia patients.read more...
Benzinga
US stocks lower as Nasdaq falls 200 points, Dow down 0.04% and S&P 500 down 0.37%. Energy shares up 1.8%, tech stocks down 1.6%. Brady Corp reports strong earnings. Sunshine Biopharma, Virax Biolabs...
Benzinga
Jim Cramer on Design Therapeutics: Pure Spec, Pure Spec...
Yahoo! Finance: News
Cramer likes Silicon Motion, whose shares fell 2.2% to settle at $263.85 on Thursday. Wynn shares declined 0.8% to close at $95.43.read more...
Benzinga
Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Wall Street Zen downgraded Design Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat

Advertisement|Remove ads.